Press Releases

PTC Therapeutics, Inc. is committed to serving the interests of all our stakeholders.
Living with
Duchenne Muscular Dystrophy,
DANYA - Duchenne Muscular Dysthropy- Ukraine

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Sep 28, 2023 PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
- Translarna CHMP opinion re-examination request to be submitted - SOUTH PLAINFIELD, N.J. , Sept. 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today further strategic prioritization and associated workforce reduction. The portfolio prioritization continues the process
Sep 15, 2023 CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
- Conference call to be held at 8: 45 am EDT - SOUTH PLAINFIELD, N.J. , Sept. 15, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the
Sep 07, 2023 PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
- 2023 recipients include patient advocacy organizations in Australia and Brazil - SOUTH PLAINFIELD, N.J. , Sept. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the two recipients of its 2023 STRIVE Awards for Duchenne Muscular Dystrophy.
Aug 30, 2023 PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , Aug. 30, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:     Citi 2023 18 th Annual BioPharma Conference Wednesday, Sept. 6 , at 9:40 a.m.
Aug 28, 2023 PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
- Results from the APHENITY trial in PKU and long-term extension study including Phe tolerance to be highlighted - SOUTH PLAINFIELD, N.J. , Aug. 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from the APHENITY clinical trial and long-term extension study
Aug 03, 2023 PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
– Second-quarter 2023 total revenue of $214 million , representing 29% year-over-year growth – – Positive APHENITY and PIVOT-HD data readouts in the second quarter – – Numerous regulatory milestones planned for the second half of 2023 –  SOUTH PLAINFIELD, N.J. , Aug.
Jul 21, 2023 CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy
- Following ratification by the European Commission , Evrysdi will be available to treat all spinal muscular atrophy patients, including babies from birth - SOUTH PLAINFIELD, N.J. , July 21, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal
Jul 20, 2023 PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results
SOUTH PLAINFIELD, N.J. , July 20, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Aug.
Jul 19, 2023 PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize
-- Dr. Jacobson recognized for his pioneering work in nonsense-mediated mRNA decay -- SOUTH PLAINFIELD, N.J. , July 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Allan Jacobson , Ph.D., co-founder of PTC and member of the Board of Directors, was presented the
Jul 18, 2023 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , July 18, 2023 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on July 13, 2023 , the company approved non-statutory stock options to purchase an aggregate of 66,380 shares of its common stock and 30,685 restricted stock units ("RSUs"), each